IMA Ikena Oncology, Inc. Future Price to Earnings
The projected P/E valuation for ImageneBio Inc (IMA) reflects the asset's price dynamics, with the current level standing at 0.00. This high valuation is driven by a biotech targeted therapy system that retains patients through unique molecules. The development of drugs designed to block tumor metabolism creates a closed patent perimeter. The strategy's effectiveness is further bolstered by partnerships with medical centers to develop cutting-edge cancer treatments.
Ikena Oncology, Inc. (IMA) - metric breakdowns and financial figures
- stock quotes and analyst forecast:
- market capitalization data:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
- company profitability and valuation multiples indicators:
IMA - Net Profit|Projected Future Earnings ImageneBio Inc|IMA - Market Cap to Net Income Ratio|Forward P/E Multiple ImageneBio Inc|IMA - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ImageneBio|IMA - Operating profit before amortization|Net earnings per share (EPS TTM) Ikena Oncology|IMA - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth ikenaoncology.com|IMA - Earnings per share growth in current year|Earnings growth forecast for next year ImageneBio Inc
Analysis of all company metrics:Ikena Oncology
To balance operational risks and return on equity, it is essential to analyze the forward P/E ratio of ImageneBio Inc (IMA), which compares the current business value to projected net income. In the case of ImageneBio Inc (IMA), the high valuation expectations are justified by the patent protection of metabolic inhibitors and FDA barriers, rendering the investment resilient to competition even during periods of temporary multiple expansion.
Main competitors
Forward P/E Multiple ARGX|Market Cap to Projected Earnings BioNTech Inc.|Future Price to Earnings abivax.com ABVX|ADMA - Projected Price to Earnings|PTGX - Future Price to Earnings|immunovant.com (IMVT) - Projected Price to Earnings|KNSA (Kiniksa) - Projected Price to Earnings|Grifols SA (GRFS) - Forward P/E Multiple|Future Price to Earnings Adaptive Biotechnologies Corp|Price to Future Earnings Ratio CLDX (Celldex Corp)|Forward P/E Multiple AUPH|BCRX - Projected Price to Earnings Ratio|Forward P/E Multiple VERA (Vera Therapeutics)|Market Cap to Projected Earnings Dianthus Therapeutics Inc (DNTH)|PHVS - Future Price to Earnings|AbCellera Biologics (ABCL) - Projected Price to Earnings|TRML: Forward P/E Multiple|precigen.com (PGEN) - Forward P/E Multiple|PHAR (Pharming Group) - Forward P/E Multiple|NKTR - Forward Price to Earnings Multiple|Forward P/E Multiple UPB|ZBIO - Projected Price to Earnings Ratio|Future Price to Earnings Immunome, Inc. IMNM|GOSS: Price to Future Earnings Ratio|KalVista Pharmaceuticals, Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio Septerna, Inc.|PVLA: Forward P/E Multiple|SVRA (Savara Pharma) - Future Price to Earnings|RIGL (Rigel Pharmaceuticals) - Forward P/E Multiple|anaptysbio.com (ANAB) - Market Cap to Projected Earnings|Future Price to Earnings Astria Therapeutics, Inc. (ATXS)|ENGN - Projected Price to Earnings Ratio|RAPT Therapeutics, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple JBIO|Aclaris Therapeutics - Forward P/E Multiple|Market Cap to Projected Earnings kyvernatx.com KYTX|Tiziana Life Sciences Ltd (TLSA) - Future Price to Earnings|Price to Future Earnings Ratio CABA|VTYX (Ventyx Bio) - Forward P/E Multiple|Projected Price to Earnings Theratechnologies, Inc (THTX)|Forward P/E Multiple AVTX|Market Cap to Projected Earnings eledon.com|Future Price to Earnings Agenus Inc. AGEN|CLYM - Projected Price to Earnings|Zura Bio Limited - Forward P/E Multiple|ATYR - Forward P/E Multiple|adagene.com (ADAG) - Future Price to Earnings|Price to Expected Earnings Ratio STTK (Shattuck Labs)|EQ (Equillium Inc) - Forward P/E Multiple|CNTB: Future Price to Earnings Multiple|Forward P/E Multiple IMUX|Forward P/E Multiple atarabio.com (ATRA)|Future Price to Earnings InflaRx IFRX|Future Price to Earnings Multiple XFOR|ACET - Future Price to Earnings|Celularity Inc. (CELU) - Projected Price to Earnings|INMB: Forward P/E Multiple|Barinthus Biotherapeutics Corp (BRNS) - Forward P/E Multiple|Projected Price to Earnings KZR|SABS: Future Price to Earnings Multiple|Forward P/E Multiple AKTX|Market Cap to Projected Earnings enlivex.com|Future Price to Earnings Q32 Bio QTTB|GOVX - Projected Price to Earnings|EDSA - Future Price to Earnings|ibioinc.com (IBIO) - Projected Price to Earnings|CARM (carismatx.com) - Projected Price to Earnings|XTL Biopharmaceuticals Ltd (XTLB) - Forward P/E Multiple|Future Price to Earnings Bolt Biotherapeutics Inc.|Price to Future Earnings Ratio HCWB (HCW Biologics Inc)|Forward P/E Multiple APVO|AIM - Projected Price to Earnings Ratio|Forward P/E Multiple ADTX (Aditxt, Inc.)|Market Cap to Projected Earnings GRI Bio Inc (GRI)|XRTX - Future Price to Earnings|Vyome Therapeutics (HIND) - Projected Price to Earnings|REVB: Forward P/E Multiple|indaptusrx.com (INDP) - Forward P/E Multiple|SCNI (Scinai Immunotherapeutics Ltd.) - Forward P/E Multiple|CALI - Forward Price to Earnings Multiple|Forward P/E Multiple AFMD|ALLK - Projected Price to Earnings Ratio|Future Price to Earnings HOOKIPA Pharma HOOK|IGMS: Price to Future Earnings Ratio|iTeos Therapeutics, Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio Ocean Biomedical Inc|TCBP: Forward P/E Multiple|THRD (Third Harmonic Bio Inc) - Future Price to Earnings
